TIGIT and non-small cell lung carcinoma: Together, these findings underscore that targeting alternative inhibitory checkpoints such as LAG-3, TIGIT, TIM-3, and VISTA can reinvigorate antitumor immunity in NSCLC, supporting a paradigm shift toward multi-checkpoint blockade strategies.